Abstract
Pazopanib (Votrient), an oral, multitargeted tyrosine kinase inhibitor that was previously approved by the FDA for advanced renal cell carcinoma, recently gained FDA approval for select patients with soft-tissue sarcoma as well. Learn more about this agent, including the studies that led to its approval, its adverse event profile, and other implications for the AP in oncology.
